1. |
Page DL. Cancer risk assessment in benign breast biopsies. Human Pathol, 1986; 17(8)∶871.
|
2. |
李樹玲.乳腺癌.見:中華人民共和國醫政司編.中國常見惡性腫瘤診治規范(第八分冊).北京:北京醫科大學中國協和醫科大學出版社,1991∶25~58.
|
3. |
Gusterson BA, Gullick WJ, Venter DJ, et al. Immunohistochemical localization of Cerb B2 in human breast carcinomas. Mol Cell Probes, 1988; 2(1)∶383.
|
4. |
Slamon DJ, Clark GM, Wong SG, et al. Huamn breast cancer:correlation of relapse and survival with amplification of the HER2/neu oncogen. Science, 1987; 235(4785)∶177.
|
5. |
Bacus SS, Ruby SG, Weinberg DS, et al. HER2/neu oncoprotein expression and proliferation in breast cancer. Am J Pathol, 1990; 137(1)∶103.
|
6. |
葉鋒,黃冰,黃書偉.乳腺腫瘤中Cerb B2癌基因產物的表達及意義.中華病理學雜志,1993; 22(2)∶104.
|
7. |
Hamna W, Kahn HJ, Andrulis I, et al. Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Mod Pathol, 1990; 3(4)∶455.
|
8. |
Lodato RF, Maguire HC, Greene MI, et al. Immunohistochemical evaluation of Cerb B2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of breast. Mod Pathol, 1990; 3(4)∶449.
|
9. |
Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of Cerb B2 in situ breast carcinoma: a detailed morphological analysis. J Pathol, 1990; 161(1)∶7.
|